Skip to main content

CYCN

Stock
Health Care
Biotechnology

Performance overview

CYCN Price
Price Chart

Forward-looking statistics

Beta
1.25
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Company info

SectorHealth Care
IndustryBiotechnology
Employees18
Market cap$6.4M

Fundamentals

Enterprise value$5.7M
Revenue$2.1M
Revenue per employee
Profit margin-141.47%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.15
Dividend per share
Revenue per share$0.82
Avg trading volume (30 day)$80K
Avg trading volume (10 day)$127K
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio-2.56
Price to sales5.75
P/E Ratio-2.56
Enterprise Value to Revenue2.74
Price to book1.17

Upcoming events

Next earnings dayMay 12, 2023
Next dividend day
Ex. dividend day

News

Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates

Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research (August 9, 2022)
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Cyclerion Therapeutics Inc's (NASDAQ: CYCN) preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease.  The data will be presented at the.

Benzinga (June 17, 2022)
Cyclerion Therapeutics Trading Near Cash; Offers A Favorable Risk Reward Opportunity

The company evaluated praliciguat in 2 diseases, diabetic nephropathy and HFpEF, which are very complex and difficult-to-treat.

Forbes (October 31, 2019)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free